Invitae Invitae Bets on Oncology Portfolio to Drive Growth as it Streamlines, Integrates Test Services Premium In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings. JP Morgan Healthcare Conference, Day 3: Invitae, NanoString, Bio-Rad, Olink, More Highlights from the third day included Invitae's plans for its testing business and updates on instrument placements by NanoString Technologies and Olink. Invitae Preliminary Q4 Revenues in Line With Wall Street Estimate Exited businesses and geographies led a year-over-year Q4 revenue decline, while annual revenues are expected to grow relative to 2021. Losses Deep and Widespread as GenomeWeb Top 40 Drops 34 Percent in 2022 All but two Top 40 companies declined, with over half losing more than 50 percent of their value and 13 companies losing three-quarters of their value or more. GenomeWeb Top 40 Down 3 Percent in December, Though More Resilient Than Broader Market The Dow Jones Industrial Average was down 4 percent, while the Nasdaq fell 9 percent, and the Nasdaq Biotech Index was down 3 percent. Dec 30, 2022 Top 10 Articles on GenomeWeb in 2022: Illumina, Invitae, 10x Genomics, Natera, Element, Ultima, More Dec 21, 2022 Genomics Firms Tackle Carbon Emissions, Face Obstacles to Net-Zero Goals From Suppliers, Shipping Premium Dec 20, 2022 Invitae Sells Archer NGS Research Assays to Integrated DNA Technologies for $48M Dec 13, 2022 Invitae Aims for Transparency With Newly Issued Patient Data Use Report Premium Dec 7, 2022 Invitae, OptraHealth Resolve Chatbot Patent Dispute Dec 2, 2022 In Brief This Week: BC Platforms, Thermo Fisher Scientific, Jumpcode Genomics, More Nov 8, 2022 Invitae Q3 Revenues Rise 17 Percent as Company Revises Cash Burn Guidance Nov 1, 2022 Epilepsy Management Often Shifts After Multigene Panel Testing, Study Finds Oct 27, 2022 Invitae, AstraZeneca Partner for Cholangiocarcinoma Study Using Ciitizen Data Platform Oct 10, 2022 Invitae's Ciitizen Platform Aims to Break Down Barriers for Rare Disease Patients and Researchers Premium Oct 4, 2022 Nonprofit's Efforts With Payors to Assess NGS Labs' Variant Interpretations Spark Debate Premium Oct 3, 2022 Highmark Asks Labs for Additional Validation Data on Cancer NGS Tests; Will Other Insurers Follow? Premium Sep 22, 2022 Universal Genetic Testing in Breast Cancer Further Supported in New Invitae-Led Study Sep 16, 2022 In Brief This Week: Thermo Fisher Scientific, DNAnexus, Precipio, Delfi Diagnostics, Streck, More Sep 1, 2022 GenomeWeb Top 40 Down 11 Percent in August, Reversing Previous Month's Gains Aug 30, 2022 Hereditary Neuropathy Foundation Aims to Provide 'One-Stop' Hub for CMT Genetic Testing Premium Aug 18, 2022 Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change Premium Aug 11, 2022 Expanded Genetic Testing Leads to Additional Cardiomyopathy, Arrhythmia Diagnoses Aug 10, 2022 Oncology Business Pushes Invitae's Q2 Revenues up 18 Percent Aug 1, 2022 GenomeWeb Top 40 Rises 10 Percent in July, Following Upward Swing in Broader Market Load More Breaking News Cancer Prognoses Informed by Module-Based Approach, Study Finds People in the News at Illumina, Centogene, BioSkryb New Products Posted to GenomeWeb: Bio-Rad, BD, Analytik Jena, BioMérieux Genetic Technologies to Raise A$5M in Direct Stock Offering In Brief This Week: SD Biosensors, Meridian, Oncocyte, Opko Health, GeneDx, More The Scan Study Reveals New Details About Genetics of Major Cause of Female Infertility Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency. Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis. Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven. White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.